Centrul De Oncologie-Euroclinic S.R.L.
- Address
- lock Available on a paid plan
Centrul De Oncologie-Euroclinic S.R.L. - Advanced Oncology Research Center
Centrul De Oncologie-Euroclinic S.R.L. is a specialized oncology research facility with extensive expertise in advanced and metastatic cancer therapeutics. The center demonstrates particular strength in conducting complex Phase 2 and Phase 3 clinical trials evaluating novel immunotherapies, targeted therapies, and combination treatment regimens across multiple cancer types.
- Non-Small Cell Lung Cancer (NSCLC) with focus on KRAS G12C mutations, PD-L1 expression, and advanced-stage disease management
- Gastrointestinal malignancies including hepatocellular carcinoma, biliary tract cancer, and esophageal squamous cell carcinoma
- Melanoma and breast cancer with emphasis on HER2-positive and hormone receptor-positive subtypes
- Biosimilar and innovative immunotherapy development, particularly pembrolizumab-based regimens and checkpoint inhibitor combinations
The research center has established itself as a key site for evaluating immune checkpoint inhibitors, targeted molecular therapies, and antibody-drug conjugates in both first-line and refractory settings. With significant experience in biomarker-driven trials, the facility specializes in precision oncology approaches including KRAS G12C-targeted treatments, HER2-directed therapies, and MET-driven cancer investigations. Their portfolio reflects strong capabilities in conducting comparative effectiveness studies and complex multi-arm trials involving novel drug combinations with chemotherapy backbones.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 57 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 56 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrul De Oncologie-Euroclinic S.R.L.
lock Showing 1 of 37 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma | Regeneron Pharmaceuticals Inc. | Phase III | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 57 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 13 | Unknown | 2021-03-17 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.